Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
fetuin-A CRISPR/Cas9 KO Plasmid (h): sc-401125
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- fetuin-A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the fetuin-A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: fetuin-A Antibody (H-4): sc-133146
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
fetuin-A CRISPR/Cas9 KO Plasmid (h) | sc-401125 | 20 µg | $397.00 |
Overview
AHSG encodes fetuin-A, a secreted glycoprotein produced predominantly by hepatocytes that circulates in plasma and associates with mineral and lipoprotein complexes. Fetuin-A modulates extracellular mineral homeostasis by binding calcium and phosphate, influencing calciprotein particle formation and controlling ectopic calcification, and it also interacts with transforming growth factor-β/BMP signaling to shape osteogenic differentiation programs. As a multifunctional serum protein, fetuin-A is frequently studied in the context of metabolic inflammation, insulin signaling regulation, and macrophage responses, linking AHSG biology to cardiometabolic and calcification-related phenotypes. Altered AHSG expression or fetuin-A levels have been associated with liver function changes and systemic processes relevant to atherosclerotic calcification, chronic kidney disease mineral imbalance, and metabolic syndrome models.
fetuin-A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the AHSG gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the AHSG together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the AHSG open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish fetuin-A protein expression.
This CRISPR knockout system enables efficient generation of AHSG-deficient cell models for investigation of fetuin-A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting AHSG exon(s) critical for fetuin-A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple AHSG genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by fetuin-A CRISPR/Cas9 KO Plasmid (h) and fetuin-A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the AHSG locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by fetuin-A HDR Plasmid (h) and fetuin-A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by AHSG homology arms to support homology-directed repair at defined AHSG target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.